Gilead Sciences, Inc. GILD Archived
-9.95%This entry is more than 3 months old and has been archived. Prices reflect the last update.
✅ Key Summary
Gilead Sciences, Inc. has demonstrated robust performance driven by its antiviral drug portfolio. Recent financial results indicate steady revenue growth, although the stock faces challenges in a competitive landscape. With a market capitalization of approximately $174 billion, its current valuation reflects an elevated basis point discrepancy.
🏢 Company Overview
Gilead Sciences, Inc. specializes in innovative therapeutics, particularly in antiviral treatments. The company has reported consistent revenue growth, largely attributed to its key products in the HIV and hepatitis C markets. Recent earnings have exceeded analyst expectations, showing resilience amid market fluctuations. However, the stock has experienced volatility due to competitive pressures and evolving market dynamics. Investors are closely monitoring Gilead's pipeline for upcoming therapies that could further enhance its growth trajectory. The current stock price of $140.30 suggests a notable basis point deviation, indicating potential undervaluation or market apprehension. Analysts remain cautiously optimistic about the company's long-term prospects. Continued investment in research and development is crucial for maintaining its competitive edge.
📰 Related News
-
Gilead's New HIV Treatment Receives FDA ApprovalPositive impact on stock as it expands product offerings.
-
Analysts Adjust Price Targets Following Earnings ReportMixed impact reflecting differing outlooks on future growth.
-
Competitor Launches New Antiviral TreatmentNegative impact due to increased competition in the market.
🏭 Competitor Comparison
-
AbbVie Inc. ABBVFocuses on immunology and virology, with strong competitive products.
-
Vertex Pharmaceuticals VRTXSpecializes in cystic fibrosis treatments, presents a different market focus.
-
Bristol-Myers Squibb BMYDiversified portfolio with significant oncology presence, differing therapeutic areas.
📅 Gilead Sciences, Inc. discovery history
This stock has been discovered 6 times.
| Discovered | Discovery price | Current price | Return |
|---|---|---|---|
| Sep 17, 2026 | $150.89 | $168.08 | +11.39% |
| Aug 12, 2026 | $135.87 | $170.87 | +25.76% |
| May 6, 2026 | $136.30 | $135.25 | -0.77% |
| Jan 30, 2026 | $141.95 | $130.84 | -7.83% |
| Dec 24, 2025 | $125.67 | $138.11 | +9.90% |